Business Wire

Cherwell Now Offers Automated Discovery and Dependency Mapping (DDM) Powered by Resolve Systems

Share

Cherwell Software LLC, a leading provider of IT Service Management (ITSM) and Enterprise Service Management (ESM) solutions, joins forces with Resolve Systems, a leader in enterprise automation and AIOps, to help companies better manage their complex IT environments through workflow automation and auto-discovery and dependency mapping. Cherwell is now an official reseller of Resolve products and can seamlessly deliver the integrated offering to their customers. Cherwell selected Resolve’s automated discovery and dependency mapping solution based on its robust capabilities and customer success.

The collaboration between Resolve and Cherwell provides a complete solution for streamlining IT operations and accelerating service delivery. Combining best-in-class ITSM and robust discovery and dependency mapping immediately provides customers deep visibility into complex, hybrid environments, while also forging a strong foundation to advance AIOps initiatives.

“By partnering with one of the leaders in enterprise service management and ITSM, we’re able to offer a comprehensive solution to automating IT operations and accelerating service desk transformation,” said Rob Kelsall, VP of Global Sales Engineering for Resolve. “We look forward to helping Cherwell customers achieve agile, autonomous operations, starting with automated discovery and dynamic dependency mapping.”

“As a fellow leader in the domain, we couldn’t be more pleased that Resolve is expanding their collaboration with us. Together, our goal is to offer exceptional, end-to-end solutions for the entire enterprise,” said Scott Gainey, chief marketing officer of Cherwell.

By combining Resolve’s discovery and dependency mapping solution with Cherwell ITSM, customers can:

  • Eliminate manual work by automating discovery and real-time updates to their Cherwell CMDB
  • Identify and track dynamic, multi-layer relationships between applications and hybrid infrastructure
  • Auto-generate complex topology maps to visualize infrastructure relationships and facilitate troubleshooting

Resolve integrates seamlessly with Cherwell’s flagship offering, Cherwell Service Management — delivered on Cherwell's powerful and flexible no-code CORE™ platform. Cherwell enables IT, HR, Facilities, and other teams to implement, automate and modernize service and support processes to meet new and evolving needs — at a fraction of the cost and complexity of other tools.

Resolve’s discovery and dependency mapping product is part of their comprehensive automation and AIOps platform, which is integrated with Cherwell’s IT Service Management® solution. Resolve provides full-stack visibility into complex, hybrid IT environments by performing agentless auto-discovery of all physical and virtual entities, mapping dependencies, and creating topology maps that enable IT teams to see what they are managing. This integration can be found on the Cherwell Marketplace.

To learn more about Cherwell’s new discovery and dependency mapping, powered by Resolve, visit cherwell.com/products/it-service-management/discovery-and-dependency-mapping/.

About Cherwell

Cherwell (@Cherwell) empowers organizations to transform their business through the rapid adoption and easy management of digital services. Cherwell’s adaptable platform has enabled thousands of organizations to modernize their business operations with customizable service management, automation, and reporting across the enterprise. For more information, visit: https://www.cherwell.com.

About Resolve Systems

Resolve helps IT teams achieve agile, autonomous operations with an industry-leading, enterprise automation and AIOps platform. By combining insights from artificial intelligence with powerful, cross-domain automation, Resolve handles a wide array of IT operations – from dependency mapping, event correlation, and predictive analytics to intelligently automating actions based on those findings. Purpose-built to address challenges posed by increasing IT complexity, Resolve enables organizations to maximize operational efficiency, reduce costs, quickly troubleshoot and fix problems, and accelerate service delivery. See why the Fortune 1000, leading MSPs, and the largest communication service providers on the planet trust Resolve to power millions of automations every day. Learn more at resolve.io or follow us on Twitter @ResolveSystems.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contacts:
Scott Gainey, Cherwell
scott.gainey@cherwell.com

Holly Abbott, Say Communications (For Resolve)
resolve@saycomms.co.uk

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 14:30:00 CEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new

MEDIA ALERT: Wolters Kluwer expert comments on European Parliament vote to pass amendment implementing Basel III reforms26.4.2024 14:00:00 CEST | Press release

The European financial landscape saw a milestone event this week, as the EU Parliament passed the Amendment to Regulation (EU) No 575/2013, implementing the Basel III finalization within Europe. This monumental step forward comes with the adoption of the Capital Requirements Regulation (CRR3) amendments, which are part of a broader legislative package, including amendments to Directive 2013/36/EU, known as the Capital Requirements Directive or CRD. Jeroen Van Doorsselaere, Vice President of Global Product & Platform Management, Wolters Kluwer FRR, said: “The adoption of the Capital Requirements Regulation (CRR3) amendments represents a landmark change for the banking industry, designed to strengthen the framework for risk-based capital requirements and address ESG risks. “This is a major overhaul of the capital requirements framework, impacting various aspects, including credit risk, operational risk, market risk, and the capital floor. Whereas other significant jurisdictions, includin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye